Gerhartz H H, Liss E, Schmidt H
J Cancer Res Clin Oncol. 1979 Jul 27;94(3):257-63. doi: 10.1007/BF00419285.
A cyclophosphamide-resistant subline of a Yoshida ascites tumor was developed by giving increasing doses of the drug after transplantation. The effect of several alkylating agents on the cell proliferation of both the sensitive and resistance cell line was compared establishind dose response curves and D50 values. The developed subline revealed a 260 fold resistance to cyclophosphamide. It was completely cross-resistant to hydroperoxycyclophosphamide, whereas for triaziquone, N-oxide-mustard, and N-methyl-mustard only a partial cross resistance existed. These results give further evidence that cyclophosphamide and hydropeoxycyclophosphamide have the same mechanism of action. Regarding the other alkylating agents the results demonstrate differences concerning either the molecular mode of action or protecting effects. A decreased activation or uptake of substance is probably not the base for resistance.
通过在移植后给予递增剂量的环磷酰胺,培育出了吉田腹水瘤的环磷酰胺耐药亚系。比较了几种烷化剂对敏感细胞系和耐药细胞系细胞增殖的影响,建立了剂量反应曲线和半数致死剂量(D50)值。所培育的亚系显示出对环磷酰胺260倍的耐药性。它对氢过氧环磷酰胺完全交叉耐药,而对于三嗪醌、N-氧化物芥子气和N-甲基芥子气,仅存在部分交叉耐药。这些结果进一步证明环磷酰胺和氢过氧环磷酰胺具有相同的作用机制。关于其他烷化剂,结果表明在作用分子模式或保护作用方面存在差异。物质激活或摄取的减少可能不是耐药的基础。